Guggenheim Maintains Buy Rating on Roivant Sciences
Guggenheim has reaffirmed its 'Buy' rating for Roivant Sciences, reflecting a continued positive outlook from the firm.
Stocks · News reference
Roivant Sciences (NASDAQ:ROIV) reported second-quarter financial results on Monday. The transcript from the company’s second-quarter earnings call has been provided below.This transcript is brought to you by Benzinga
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Guggenheim has reaffirmed its 'Buy' rating for Roivant Sciences, reflecting a continued positive outlook from the firm.
An insider at Roivant Sciences Ltd. sold company shares valued at approximately $12.47 million, according to a recent SEC filing.
Analysts adjusted targets: RIOT upgraded to Buy; WIX downgraded to Underperform; targets also changed for MNDY, ONTO, ROIV, FERG and NVDA.
Roivant Sciences announced its financial results for the second quarter ended September 30, 2026, highlighting strong early revenue for LISRAYA and progress across its clinical pipeline.